CRIS Current Research Information System

RIZZELLO, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.697
NA - Nord America 1.723
EU - Europa 1.192
SA - Sud America 152
AF - Africa 126
Continente sconosciuto - Info sul continente non disponibili 123
OC - Oceania 4
Totale 6.017
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.651
VN - Vietnam 979
CN - Cina 598
SG - Singapore 570
IT - Italia 498
HK - Hong Kong 149
GB - Regno Unito 119
DE - Germania 118
BR - Brasile 106
KR - Corea 102
NL - Olanda 83
IN - India 78
FR - Francia 77
BD - Bangladesh 75
SE - Svezia 67
CI - Costa d'Avorio 51
FI - Finlandia 45
IE - Irlanda 36
JP - Giappone 34
RU - Federazione Russa 31
CA - Canada 29
SC - Seychelles 29
AT - Austria 26
AR - Argentina 23
PH - Filippine 23
ZA - Sudafrica 23
MX - Messico 19
ES - Italia 18
BG - Bulgaria 15
TH - Thailandia 13
TG - Togo 12
TW - Taiwan 11
ID - Indonesia 9
JO - Giordania 9
PL - Polonia 9
CH - Svizzera 8
IQ - Iraq 8
UA - Ucraina 8
EE - Estonia 7
TR - Turchia 7
JM - Giamaica 6
UZ - Uzbekistan 6
BE - Belgio 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
SA - Arabia Saudita 5
SV - El Salvador 5
CL - Cile 4
CO - Colombia 4
GR - Grecia 4
MY - Malesia 4
PK - Pakistan 4
AU - Australia 3
CR - Costa Rica 3
DZ - Algeria 3
PE - Perù 3
PT - Portogallo 3
VE - Venezuela 3
BS - Bahamas 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GH - Ghana 2
GT - Guatemala 2
HN - Honduras 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
PY - Paraguay 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
ZM - Zambia 1
Totale 5.896
Salva come PNG Salva come JPEG
Città #
Singapore 405
Ho Chi Minh City 296
Hanoi 241
Ashburn 235
Hefei 213
Bologna 164
Hong Kong 143
San Jose 132
Dallas 126
Chandler 107
Seoul 97
Southend 71
Fairfield 63
Council Bluffs 61
Abidjan 51
Beijing 51
New York 49
Haiphong 46
Santa Clara 43
Los Angeles 39
Dublin 36
Lauterbourg 35
Woodbridge 33
Boardman 29
Wilmington 29
Milan 28
Seattle 27
São Paulo 27
Houston 26
Tokyo 25
Helsinki 23
Munich 23
Cambridge 22
Hyderabad 22
Princeton 22
Da Nang 20
Bengaluru 19
Amsterdam 18
Vienna 18
Frankfurt am Main 17
Lappeenranta 17
Biên Hòa 16
Sofia 15
Ann Arbor 14
Ha Long 14
Johannesburg 14
Quận Bình Thạnh 14
Buffalo 13
Chicago 13
Turin 13
Bremen 12
Can Tho 12
Lomé 12
Thái Nguyên 12
Guangzhou 11
Hải Dương 11
Atlanta 10
Fabriano 10
Ninh Bình 10
Nuremberg 10
Redondo Beach 10
Rome 10
Amman 9
Dongguan 9
Mexico City 9
Nanjing 9
Quận Một 9
Redmond 9
Điện Bàn 9
Bắc Ninh 8
Falkenstein 8
Jakarta 8
Nanchang 8
Tongling 8
Bến Tre 7
Dearborn 7
Florence 7
London 7
Orem 7
San Diego 7
Shanghai 7
Shenzhen 7
Toronto 7
Zhengzhou 7
Berlin 6
Bern 6
Montreal 6
Naples 6
New Delhi 6
Padova 6
Paris 6
Phoenix 6
Quận Phú Nhuận 6
Thu Dau Mot 6
Vũng Tàu 6
Warsaw 6
Westminster 6
Ankara 5
Brooklyn 5
Bắc Giang 5
Totale 3.671
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 181
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 154
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 131
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 127
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 126
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 125
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 124
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 102
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 101
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 98
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 94
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 88
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 87
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 81
Totale 6.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.181
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022257 0 13 15 28 13 10 10 22 16 38 51 41
2022/2023450 35 48 12 75 41 36 16 18 77 16 45 31
2023/2024249 16 29 14 18 17 50 7 50 6 17 17 8
2024/2025973 66 59 88 95 72 31 71 32 34 108 126 191
2025/20263.510 323 793 268 273 256 158 254 103 575 235 144 128
2026/2027209 100 109 0 0 0 0 0 0 0 0 0 0
Totale 6.017